The Cell and Gene Therapy Catapult (CGT Catapult) has emphasized the importance of advanced therapies in helping the UK Government achieve its goal of becoming one of the top three global life sciences economies by 2035. In their latest annual review, CGT Catapult explains how they are making progress in the cell and gene therapy industry, which benefits both the economy and patients. Over the past financial year, they worked with 70 companies, 60% of which were small to medium-sized UK businesses. Together, these companies raised over £177 million. More patients are now able to access new treatments. By April, 17 therapies had been approved and made available for use. In 2024, 9.5% of global advanced therapy clinical trials included the UK, with nine companies supported by CGT Catapult conducting trials in the UK. Matthew Durdy, Chief Executive of the Cell and Gene Therapy Catapult, said: “We are grateful to our partners in industry, healthcare, and government who have worked with us over the past year. Together, we have created partnerships that supported industry growth and helped the UK maintain its leading position in advanced therapies.” He added: “The advanced therapies sector is crucial for achieving the Government’s goals of sustainable economic growth and improved health outcomes for patients.”